Business
Hoth Therapeutics Expands Oncology Pipeline with Dual Patent Filings Establishing Novel Oncology Dermatology IP Platform
Hoth Therapeutics (NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing innovative therapies for underserved medical needs, today announced the filing of two U.S. provisional patent applications that significantly expand the Company's intellectual property portfolio and establish a new oncology-focused dermatology platform targeting treatment-induced skin toxicity from modern cancer therapies.
About this update from Hoth Therapeutics, Inc.
[{"type":"text","content":"NEW YORK, Jan. 2, 2026 /PRNewswire/ -- Hoth Therapeutics (NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing innovative therapies for underserved medical needs, today announced the filing of two U.S. provisional patent applications that significantly expand the Company's intellectual property portfolio and establish a new oncology-focused dermatology platform targeting treatment-induced skin toxicity from modern cancer therapies.","length":460,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Hoth Therapeutics Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Hoth Therapeutics Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":68,"url":"https://media.zenfs.com/en/prnewswire.com/a168928171a9653a66d38f6c5e666beb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/r2Ptel_Ut1tf_dA2SUFY0g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTEyMDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/a168928171a9653a66d38f6c5e666beb","width":400,"height":68}},"href":"https://mma.prnewswire.com/media/644804/Hoth_Therapeutics_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The first provisional patent application, titled covering the topical treatment of radiation-induced skin toxicity in oncology patients.","length":136,"tagName":"p"},{"type":"text","content":"The second provisional patent application, titled addressing dermatologic toxicities associated with emerging targeted cancer therapies, including second and third menin inhibitors.","length":181,"tagName":"p"},{"type":"text","content":"Together, these dual filings secure priority intellectual property rights around the use of HT-001 to treat dermatologic toxicities across multiple oncology treatment modalities, including radiation therapy and next-generation targeted agents. As cancer treatments become more effective and patients remain on therapy longer, managing treatment-limiting skin toxicities has become a critical and growing unmet need in oncology care.","length":432,"tagName":"p"},{"type":"text","content":"Radiotherapy-induced dermatitis and dermatologic adverse effects from targeted oncology therapies frequently result in pain, inflammation, severe pruritus, infection risk, reduced quality of life, and treatment interruption or discontinuation, which can negatively impact patient ou...